Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids

Forensic Toxicology

Volumn 29, Issue 2, 2011, Pages 117-124

  Yamaori, Satoshi ^a   Maeda, Chikako ^a   Yamamoto, Ikuo ^b   Watanabe, Kazuhito ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Cannabinoid; CYP2A6; CYP2B6; Differential inhibition; Marijuana; Nicotine

Indexed keywords

CANNABIDIOL; CANNABIDIOL 2' MONOMETHYL ETHER; CANNABIDIOL 2',6' DIMETHYL ETHER; CANNABIDIVARIN; CANNABINOL; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; LIMONENE; OLIVETOL; TERPENE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME METABOLISM; HUMAN; PRIORITY JOURNAL;

CANNABIS SATIVA;

EID: 79960583719     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-011-0112-7     Document Type: Article

References (38)

1. K Kudo T Ishida W Hikiji Y Usumoto T Umehara K Nagamatsu A Tsuji N Ikeda 2010 Pattern of poisoning in Japan: selection of drugs and poisons for systematic toxicological analysis Forensic Toxicol 28 25 32 10.1007/s11419-009- 0088-8 1:CAS:528:DC%2BC3cXhtleit7g%3D
2. N Uchiyama R Kikura-Hanajiri N Kawahara Y Goda 2009 Identification of a cannabimimetic indole as a designer drug in a herbal product Forensic Toxicol 27 61 66 10.1007/s11419-009-0069-y 1:CAS:528:DC%2BD1MXos1Cgsrs%3D
3. N Uchiyama M Kawamura R Kikura-Hanajiri Y Goda 2011 Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products Forensic Toxicol 29 25 37 10.1007/s11419-010-0100-3 1:CAS:528:DC%2BC3MXhtVartr4%3D
4. W Hall L Degenhardt 2009 Adverse health effects of non-medical cannabis use Lancet 374 1383 1391 19837255 10.1016/S0140-6736(09)61037-0 1:CAS:528:DC%2BD1MXht1Ogu7fE
5. H Van Vunakis DP Tashkin M Simmons VA Clark 1988 Decreased serum cotinine levels in smokers of both tobacco and marijuana as compared with smokers of tobacco only Pharmacol Biochem Behav 30 895 898 3227038 10.1016/0091-3057(88) 90116-5 (Pubitemid 19270648)
6. M Nakajima T Yamamoto K Nunoya T Yokoi K Nagashima K Inoue Y Funae N Shimada T Kamataki Y Kuroiwa 1996 Role of human cytochrome P4502A6 in C-oxidation of nicotine Drug Metab Dispos 24 1212 1217 8937855 1:CAS:528:DyaK28XntVOisLg%3D (Pubitemid 26423061)
7. H Yamazaki K Inoue M Hashimoto T Shimada 1999 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes Arch Toxicol 73 65 70 10350185 10.1007/s002040050588 1:CAS:528:DyaK1MXitlyitbw%3D (Pubitemid 29226163)
8. H Yamanaka M Nakajima T Fukami H Sakai A Nakamura M Katoh M Takamiya Y Aoki T Yokoi 2005 CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions Drug Metab Dispos 33 1811 1818 16135656 1:CAS:528:DC%2BD2MXht1ygu7vI (Pubitemid 41697266)
9. YM Di VD Chow LP Yang SF Zhou 2009 Structure, function, regulation and polymorphism of human cytochrome P450 2A6 Curr Drug Metab 10 754 780 19702528 10.2174/138920009789895507 1:CAS:528:DC%2BC3cXhsFKlu7Y%3D
10. SL Mo YH Liu W Duan MQ Wei JR. Kanwar SF Zhou 2009 Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6 Curr Drug Metab 10 730 753 19702527 10.2174/138920009789895534 1:CAS:528:DC%2BC3cXhsFKlu7k%3D
11. ET Ogburn DR Jones AR Masters C Xu Y Guo Z Desta 2010 Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation Drug Metab Dispos 38 1218 1229 20335270 10.1124/dmd.109.031393 1:CAS:528:DC%2BC3cXos1Klsbc%3D
12. K Abass P Reponen S Mattila O Pelkonen 2011 Metabolism of α-thujone in human hepatic preparations in vitro Xenobiotica 41 101 111 21087116 10.3109/00498254.2010.528066 1:CAS:528:DC%2BC3MXjsFWhsw%3D%3D
13. EL Code CL Crespi BW Penman FJ Gonzalez TK Chang DJ Waxman 1997 Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation Drug Metab Dispos 25 985 993 9280407 1:CAS:528:DyaK2sXlsVGmsrc%3D (Pubitemid 27357697)
14. MA ElSohly D Slade 2005 Chemical constituents of marijuana: the complex mixture of natural cannabinoids Life Sci 78 539 548 16199061 10.1016/j.lfs.2005.09.011 1:CAS:528:DC%2BD2MXht1ejsrfJ (Pubitemid 41653504)
15. 9-tetrahydrocannabinol, cannabidiol and cannabinol. In: Pertwee RG (ed) Cannabinoids. Handbook of experimental pharmacology, vol 168. Springer, Berlin, pp 657-690
16. K Watanabe S Yamaori T Funahashi T Kimura I Yamamoto 2006 8-Hydroxycannabinol: a new metabolite of cannabinol formed by human hepatic microsomes Forensic Toxicol 24 80 82 10.1007/s11419-006-0016-0 1:CAS:528:DC%2BD2sXhvVant7w%3D (Pubitemid 46020951)
17. K Watanabe S Yamaori T Funahashi T Kimura I Yamamoto 2007 Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes Life Sci 80 1415 1419 17303175 10.1016/j.lfs.2006.12. 032 1:CAS:528:DC%2BD2sXislKgt7k%3D (Pubitemid 46367067)
18. K Watanabe M Fujinami S Yamaori I Yamamoto 2011 Possible involvement of Cyp3a enzymes in the metabolism of tetrahydrocannabinols by mouse brain microsomes Forensic Toxicol 29 56 60 10.1007/s11419-010-0103-0 1:CAS:528:DC%2BC3MXhtVartr8%3D
19. LM Bornheim MA Correia 1991 Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: a possible member of the cytochrome P-450IIC subfamily Mol Pharmacol 40 228 234 1875910 1:CAS:528:DyaK3MXmt1Kksro%3D
20. 1-tetrahydrocannabinol Drug Metab Dispos 20 241 246 1352216 1:CAS:528:DyaK38XisVOrsL8%3D
21. K Watanabe T Matsunaga I Yamamoto Y Funae H Yoshimura 1995 Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman Biol Pharm Bull 18 1138 1141 8535411 1:CAS:528:DyaK2MXotlGnsbs%3D
22. M Fernandes N Warning W Christ R Hill 1973 Interactions of several cannabinoids with the hepatic drug metabolizing system Biochem Pharmacol 22 2981 2987 4796885 10.1016/0006-2952(73)90184-6 1:CAS:528:DyaE2cXhtVers78%3D
23. NL Benowitz TL Nguyen RT Jones RI Herning J Bachman 1980 Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction Clin Pharmacol Ther 28 115 120 7389248 10.1038/clpt.1980.139 1:CAS:528:DyaL3cXlt1GrsL4%3D (Pubitemid 10090694)
24. W Jaeger LZ Benet LM Bornheim 1996 Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes Xenobiotica 26 275 284 8730919 10.3109/00498259609046707 1:CAS:528: DyaK28XitFKisLw%3D (Pubitemid 26128232)
25. S Yamaori M Kushihara I Yamamoto K Watanabe 2010 Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes Biochem Pharmacol 79 1691 1698 20117100 10.1016/j.bcp.2010.01.028 1:CAS:528:DC%2BC3cXjvFKmtL4%3D
26. Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K (2011) Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. doi: 10.1016/j.lfs.2011.02. 017
27. H Aramaki N Tomiyasu H Yoshimura H Tsukamoto 1968 Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies Chem Pharm Bull 16 822 826 5728171 1:CAS:528:DyaF1cXktlChu7s%3D
28. H Gohda S Narimatsu I Yamamoto H Yoshimura 1990 In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol Chem Pharm Bull 38 1697 1701 2208386 1:CAS:528:DyaK3cXlt1Gqtbs%3D (Pubitemid 20265655)
29. K Watanabe E Motoya N Matsuzawa T Funahashi T Kimura T Matsunaga K Arizono I Yamamoto 2005 Marijuana extracts possess the effects like the endocrine disrupting chemicals Toxicology 206 471 478 15588936 10.1016/j.tox.2004.08.005 1:CAS:528:DC%2BD2cXhtVKksr7P (Pubitemid 39601030)
30. JC Talakad S Kumar JR. Halpert 2009 Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs Drug Metab Dispos 37 644 650 19074527 10.1124/dmd.108.023655 1:CAS:528:DC%2BD1MXislamtbs%3D
31. M Stiborová L Bořek-Dohalská P Hodek J Mráz E Frei 2002 New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen Arch Biochem Biophys 403 41 49 12061800 10.1016/S0003-9861(02)00259-X (Pubitemid 34848276)
32. JM Rae NV Soukhova DA Flockhart Z Desta 2002 Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism Drug Metab Dispos 30 525 530 11950782 10.1124/dmd.30.5.525 1:CAS:528:DC%2BD38Xjt1yqsLY%3D (Pubitemid 34456973)
33. LB von Weymarn KM Brown SE Murphy 2006 Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism J Pharmacol Exp Ther 316 295 303 10.1124/jpet.105.091306 (Pubitemid 41832609)
34. EC Siu RF Tyndale 2008 Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice J Pharmacol Exp Ther 324 992 999 18065502 10.1124/jpet.107.133900 1:CAS:528:DC%2BD1cXivVajs7s%3D (Pubitemid 351397848)
35. HH Yoo MW Lee YC Kim CH Yun DH Kim 2007 Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica gigas Drug Metab Dispos 35 1759 1765 17620343 10.1124/dmd.107.016584 1:CAS:528: DC%2BD2sXhtFansbnK (Pubitemid 47481567)
36. LL Koenigs RM Peter SJ Thompson AE Rettie WF Trager 1997 Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen Drug Metab Dispos 25 1407 1415 9394031 1:STN:280:DyaK1c%2FlslCnsQ%3D%3D (Pubitemid 28010927)
37. SC Khojasteh-Bakht LL Koenigs RM Peter WF Trager SD Nelson 1998 (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6 Drug Metab Dispos 26 701 704 9660853 1:CAS:528: DyaK1cXkvV2itLw%3D (Pubitemid 28345854)
38. H Yamanaka M Nakajima K Nishimura R Yoshida T Fukami M Katoh T Yokoi 2004 Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted Eur J Pharm Sci 22 419 425 15265511 10.1016/j.ejps.2004.04.012 1:CAS:528: DC%2BD2cXlsl2ntrw%3D (Pubitemid 38953900)